Kaiser Family members Foundation. Kaiser Health News, an editorially independent information service, is a scheduled program of the Kaiser Family Foundation, a nonpartisan health care policy research company unaffiliated with Kaiser Permanente., announced their plans today to check several potential small-molecule substances to slow or end the progression of Amyotrophic Lateral Sclerosis . This collaborative work will substantially boost our ability to identify several brand-new existing compounds related to the information gained through our gene expression profiling and proteomics attempts.D., CEO & chief scientific officer at ALS TDI.A key element in the pathobiology of cardiovascular ischemic events may be the activated platelet.6 Aspirin reduces the risk of ischemic events both among sufferers who present with an acute coronary syndrome and in secondary avoidance for patients with a brief history of myocardial infarction.7 The addition of a P2Y12 receptor antagonist to aspirin has been shown to reduce further the chance of ischemic events in this people in the first year after an acute coronary syndrome.8-11 The role of P2Y12 receptor antagonists in long-term secondary avoidance after myocardial infarction, however, is not established. Practice guidelines in the usa and Europe currently recommend treatment with a P2Y12 receptor antagonist for up to 1 year after a myocardial infarction.12-15 Ticagrelor is a potent, binding reversibly, direct-acting P2Y12 receptor antagonist.16 When put into aspirin for 12 months after an acute coronary syndrome, ticagrelor at a dosage of 90 mg twice daily reduced the rate of main adverse cardiovascular occasions including cardiovascular death, as compared with clopidogrel at a dosage of 75 mg once daily.